Published in J Manag Care Pharm on December 01, 2004
Glycemic Allostasis during Mental Activities on Fasting in Non-alcohol Users and Alcohol Users with Different Durations of Abstinence. Ann Med Health Sci Res (2014) 0.75
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care (2004) 4.17
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care (2011) 2.60
Autonomic contribution to blood pressure and metabolism in obesity. Hypertension (2006) 2.25
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol (2009) 1.93
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care (2010) 1.71
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care (2006) 1.51
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care (2007) 1.46
The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care (2011) 1.26
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes (2004) 1.20
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care (2013) 1.18
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Impact of computer-generated personalized goals on HbA(1c). Diabetes Care (2002) 1.14
Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab (2011) 1.11
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care (2013) 1.09
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J (2006) 1.08
Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2006) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Leptin: metabolic control and regulation. J Diabetes Complications (2003) 1.03
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther (2006) 1.02
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY. J Clin Lipidol (2009) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes (2003) 1.01
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol (2004) 1.01
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs (2014) 1.00
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes (2003) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care (2012) 0.96
Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother (2005) 0.95
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther (2008) 0.93
Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone (2006) 0.93
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry (2009) 0.93
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev (2009) 0.93
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes (2008) 0.90
Insulin glargine: a new basal insulin. Ann Pharmacother (2002) 0.90
Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev (2005) 0.89
Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes (2003) 0.89
Hypoglycemia associated autonomic failure. Clin Auton Res (2002) 0.88
Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.87
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Curr Diabetes Rev (2013) 0.87
Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. Diabetes (2010) 0.86
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving! Diabetes Care (2014) 0.86
Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother (2011) 0.86
Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab (2006) 0.85
Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care (2010) 0.85
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes. Diabetes (2009) 0.85
Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia. Am J Physiol Endocrinol Metab (2008) 0.84
Effect of sex on counterregulatory responses to exercise after antecedent hypoglycemia in type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 0.84
Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes. J Clin Endocrinol Metab (2002) 0.84
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications (2007) 0.84
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2015) 0.84
The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med (2003) 0.83
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats. Am J Physiol Endocrinol Metab (2007) 0.83
Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am (2005) 0.83
Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab (2005) 0.83
The American Diabetes Association diabetes research perspective. Diabetes (2012) 0.82
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2013) 0.82
Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther (2011) 0.82
NO synthase inhibition increases aldosterone in humans. Hypertension (2004) 0.82
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol (2011) 0.82
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging (2011) 0.82
The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2010) 0.82
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther (2012) 0.81
The American Diabetes Association diabetes research perspective. Diabetes Care (2012) 0.81
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol Ther (2013) 0.80
The effects of dehydroepiandrosterone sulfate on counterregulatory responses during repeated hypoglycemia in conscious normal rats. Diabetes (2004) 0.80
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. J Diabetes Complications (2011) 0.80
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.79
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab (2015) 0.79
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am J Physiol Endocrinol Metab (2005) 0.79
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep (2011) 0.79
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep (2008) 0.78
Caffeine: a cause of insulin resistance? Diabetes Care (2002) 0.78
Physical activity in adolescents with type 1 diabetes: is more better for glycemic control? Pediatr Diabetes (2009) 0.78
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol (2006) 0.78
Pramlintide: A new tool in diabetes management. Curr Diab Rep (2006) 0.78
Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) . J Clin Lipidol (2010) 0.77
Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol (2006) 0.77
Managing people at high risk for diabetes. Ann Intern Med (2006) 0.77